Gamida Cell Ltd. is a clinical stage biopharmaceutical company, which engages in the development of cell therapies that are designed to cure cancer and rare serious hematologic diseases. Its products pipeline include NiCord and NAM-NK. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone972-2659-5666
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees70
Next Earnings Date2/14/2020 (Estimated)
OptionableNot Optionable
Gamida Cell (NASDAQ:GMDA) Frequently Asked Questions
What is Gamida Cell's stock symbol?
Gamida Cell trades on the NASDAQ under the ticker symbol "GMDA."
How were Gamida Cell's earnings last quarter?
Gamida Cell Ltd (NASDAQ:GMDA) released its quarterly earnings data on Tuesday, August, 6th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.55) by $0.32. View Gamida Cell's Earnings History.
When is Gamida Cell's next earnings date?
What price target have analysts set for GMDA?
5 Wall Street analysts have issued 1-year price objectives for Gamida Cell's shares. Their predictions range from $15.00 to $23.00. On average, they expect Gamida Cell's stock price to reach $19.00 in the next year. This suggests a possible upside of 392.2% from the stock's current price. View Analyst Price Targets for Gamida Cell.
What is the consensus analysts' recommendation for Gamida Cell?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gamida Cell in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Gamida Cell.
Has Gamida Cell been receiving favorable news coverage?
Media coverage about GMDA stock has been trending positive on Friday, according to InfoTrie. The research firm rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Gamida Cell earned a news impact score of 2.5 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the company's share price in the next few days. View News Stories for Gamida Cell.
Are investors shorting Gamida Cell?
Gamida Cell saw a increase in short interest in July. As of July 31st, there was short interest totalling 30,400 shares, an increase of 52.0% from the June 30th total of 20,000 shares. Based on an average daily volume of 29,200 shares, the days-to-cover ratio is currently 1.0 days. Currently, 0.5% of the company's stock are sold short. View Gamida Cell's Current Options Chain.
Who are some of Gamida Cell's key competitors?
Some companies that are related to Gamida Cell include La Jolla Pharmaceutical (LJPC), Eiger Biopharmaceuticals (EIGR), Cellular Biomedicine Group (CBMG), ADMA Biologics (ADMA), Compugen (CGEN), Sutro Biopharma (STRO), Adaptimmune Therapeutics (ADAP), Axcella Health (AXLA), Dyadic International (DYAI), LogicBio Therapeutics (LOGC), X4 Pharmaceuticals (XFOR), Novavax (NVAX), Oncobiologics (ONS), Acorda Therapeutics (ACOR) and Windtree Therapeutics (WINT).
What other stocks do shareholders of Gamida Cell own?
Who are Gamida Cell's key executives?
Gamida Cell's management team includes the folowing people:
- Julian Adams, Chief Executive Officer & Director
- Yael Margolin, President
- Tzvi Palash, Chief Operating Officer
- Shai Lankry, Chief Financial & Accounting Officer
- Tony Peled, Chief Scientific Officer, Vice President-R&D
When did Gamida Cell IPO?
(GMDA) raised $50 million in an IPO on Friday, October 26th 2018. The company issued 3,600,000 shares at $13.00-$15.00 per share. BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and Needham & Company Oppenheimer & Co. was co-manager.
Who are Gamida Cell's major shareholders?
Gamida Cell's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Rock Springs Capital Management LP (4.13%), Noked Capital LTD (0.84%), EcoR1 Capital LLC (0.22%), Bank Hapoalim BM (0.16%) and Royal Bank of Canada (0.06%).
Which major investors are buying Gamida Cell stock?
GMDA stock was bought by a variety of institutional investors in the last quarter, including Rock Springs Capital Management LP, Noked Capital LTD, EcoR1 Capital LLC, Bank Hapoalim BM and Royal Bank of Canada.
How do I buy shares of Gamida Cell?
Shares of GMDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Gamida Cell's stock price today?
One share of GMDA stock can currently be purchased for approximately $3.86.
How big of a company is Gamida Cell?
Gamida Cell has a market capitalization of $93.50 million. The company earns $-52,930,000.00 in net income (profit) each year or ($10.53) on an earnings per share basis. Gamida Cell employs 70 workers across the globe.View Additional Information About Gamida Cell.
What is Gamida Cell's official website?
How can I contact Gamida Cell?
Gamida Cell's mailing address is 5 NAHUM HAFZADI STREET GIVAAT SHAUL, JERUSALEM L3, 91340. The company can be reached via phone at 972-2659-5666 or via email at [email protected]
MarketBeat Community Rating for Gamida Cell (NASDAQ GMDA)
MarketBeat's community ratings are surveys of what our community members think about Gamida Cell and other stocks. Vote "Outperform" if you believe GMDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GMDA will underperform the S&P 500 over the long term. You may vote once every thirty days.
